Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

IMCR – Immunocore Holdings plc ADR

Float Short %

17.51

Margin Of Safety %

-29

Put/Call OI Ratio

0.54

EPS Next Q Diff

EPS Last/This Y

0.72

EPS This/Next Y

-0.53

Price

38.78

Target Price

64.3

Analyst Recom

1.65

Performance Q

5.84

Relative Volume

0.77

Beta

0.77

Ticker: IMCR




18 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-11-10IMCR35.070.690.254034
2025-11-11IMCR35.280.690.504037
2025-11-12IMCR35.210.690.504037
2025-11-13IMCR35.370.690.004042
2025-11-14IMCR360.690.004038
2025-11-17IMCR36.580.690.254038
2025-11-18IMCR380.690.004023
2025-11-19IMCR38.650.690.604031
2025-11-20IMCR39.030.600.503814
2025-11-21IMCR39.280.600.753818
2025-11-24IMCR38.740.560.003704
2025-11-25IMCR39.860.560.003705
2025-11-26IMCR40.040.540.003805
2025-12-01IMCR37.590.540.003806
2025-12-02IMCR36.140.540.193807
2025-12-03IMCR37.870.540.503811
2025-12-04IMCR40.280.540.173815
2025-12-05IMCR38.770.540.173815
DateSymbolLatestP/C OIP/C VolTotal OI
18 items Current Page1 of 1




18 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-11-10IMCR35.00-241.2-145.3-0.63
2025-11-11IMCR35.2052.8-137.3-0.31
2025-11-12IMCR35.2852.8-109.5-0.31
2025-11-13IMCR35.4154.9-110.2-0.31
2025-11-14IMCR36.0054.9-112.3-0.31
2025-11-17IMCR36.5854.9-112.1-0.31
2025-11-18IMCR38.0659.4-115.6-0.30
2025-11-19IMCR38.6559.4-111.8-0.30
2025-11-20IMCR39.0560.0-110.8-0.30
2025-11-21IMCR39.3160.0-110.5-0.30
2025-11-24IMCR38.7460.0-106.5-0.30
2025-11-25IMCR39.8760.0-113.6-0.30
2025-11-26IMCR40.1060.0-109.5-0.30
2025-12-01IMCR37.5660.0-100.9-0.30
2025-12-02IMCR36.1760.0-102.6-0.30
2025-12-03IMCR37.8860.0-116.1-0.30
2025-12-04IMCR40.2560.0-118.6-0.30
2025-12-05IMCR38.7860.0-103.2-0.30
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
18 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-11-10IMCR-26.076.4817.29
2025-11-11IMCR-26.036.4817.29
2025-11-12IMCR-26.036.4817.28
2025-11-13IMCR-26.036.4817.28
2025-11-14IMCR-26.036.4817.28
2025-11-17IMCR-26.036.9217.28
2025-11-18IMCR-26.036.9217.28
2025-11-19IMCR-26.036.9217.28
2025-11-20IMCR-26.036.9217.28
2025-11-21IMCR-26.036.9217.28
2025-11-24IMCR-26.033.0917.28
2025-11-25IMCR-26.033.0917.28
2025-11-26IMCR-28.533.0917.51
2025-12-01IMCR-37.293.0917.51
2025-12-02IMCR-37.293.0917.51
2025-12-03IMCR-37.293.0917.51
2025-12-04IMCR-37.293.0917.51
2025-12-05IMCR-37.293.0917.51
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.19

Avg. EPS Est. Next Quarter

-0.11

Insider Transactions

-37.29

Institutional Transactions

3.09

Beta

0.77

Average Sales Estimate Current Quarter

107

Average Sales Estimate Next Quarter

110

Fair Value

27.36

Quality Score

50

Growth Score

56

Sentiment Score

36

Actual DrawDown %

49.6

Max Drawdown 5-Year %

Target Price

64.3

P/E

Forward P/E

PEG

P/S

5.15

P/B

4.96

P/Free Cash Flow

684.34

EPS

-0.58

Average EPS Est. Cur. Y​

-0.3

EPS Next Y. (Est.)

-0.82

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-7.67

Relative Volume

0.77

Return on Equity vs Sector %

-34.3

Return on Equity vs Industry %

-19.4

EPS 1 7Days Diff

EPS 1 30Days Diff

0.36

EBIT Estimation

-103.2
Immunocore Holdings plc
Sector: Healthcare
Industry: Biotechnology
Employees: 493
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat advanced cutaneous melanoma and adjuvant uveal melanoma; and brenetafusp that is in Phase 3 clinical trial to treat first-line advanced cutaneous melanoma and in a Phase 1/2 clinical trial in multiple tumor types. In addition, the company's products under development include IMC-R117C (PIWIL-1) that is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, including colorectal cancer; IMC-P115C (PRAME-HLE-A02) that is in Phase 1 clinical trial for patients with tumors that express PRAME; IMC-M113V that is in Phase 1 clinical trials for a potential functional cure in human immunodeficiency virus (HIV); and IMC-I109V that is in Phase 1 clinical trials for a potential functional cure in hepatitis B virus (HBV). Further, it develops IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-S118AI to treat type 1 diabetes; and IMC-U120AI to treat atopic dermatitis. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
stock quote shares IMCR – Immunocore Holdings plc ADR Stock Price stock today
news today IMCR – Immunocore Holdings plc ADR stock forecast ,stock prediction 2023 2024 2025
marketwatch IMCR – Immunocore Holdings plc ADR yahoo finance google finance
stock history IMCR – Immunocore Holdings plc ADR invest stock market
stock prices IMCR premarket after hours
ticker IMCR fair value insiders trading